Navigation Links
BioMarin Receives 2009 Corporate Award for the Development of Kuvan

National Organization for Rare Disorders (NORD) Recognizes BioMarin's Efforts to Expand Treatment Options for Patients with PKU

NOVATO, Calif., May 15 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received the 2009 Corporate Award from the National Organization for Rare Disorders (NORD), an organization dedicated to improving the lives of people with rare diseases. The award was presented on May 14 at NORD's annual "Partners in Progress" Gala in Washington, D.C. It recognizes BioMarin's significant achievements toward improving the lives of people living with phenylketonuria (PKU).

NORD honored BioMarin for the development of Kuvan(R) (sapropterin dihydrochloride) Tablets, the first and only prescription medication for PKU. Kuvan is indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). PKU is a rare genetic disorder that can cause brain damage and various neurological complications, including mental retardation, mental illness, seizures, tremors and cognitive problems. Designated as an orphan disease, PKU occurs in about one out of every 12,000 to 15,000 live births in the United States.

"It is a great honor to receive this award from NORD," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We are very pleased to be able to provide this important treatment option to PKU patients and we will continue to push our scientific research and product development efforts forward to meet the medical needs of PKU patients -- and those with other rare diseases."

Each year NORD selects organizations that have made a positive contribution to further the needs of the patient community and have inspired the public to do so as well. Since 2004, this is the third time BioMarin has been bestowed with this honor.

"Patients and families who live with PKU face a constant struggle to maintain their health balance, and BioMarin has been instrumental in giving PKU patients an opportunity to lower their Phe levels," said NORD president Peter Saltonstall. "We applaud BioMarin's efforts and look to more companies to make similar strides and provide treatment options to patients in rare disease communities."

In addition to attending the NORD Gala mid-month, BioMarin will participate in several PKU community events in support of PKU Awareness Month this May. Participation includes full sponsorship of a disease awareness campaign and a support program for patients who may require assistance with disease management. Locally, BioMarin employees will attend and sponsor community walks around the country and assist in fundraising efforts. For more information on PKU Awareness Month, visit

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(C) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(C) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit Information on BioMarin's website is not incorporated by reference into this press release

About NORD

NORD, celebrating its 25th anniversary this year, is a federation of individuals' and patients' organizations. The organization advocates on behalf of the rare disease community and sponsors research grants and fellowships, educational services for patients and medical professionals and other patient assistance programs. Established by leaders of rare disease patient organizations who helped get the Orphan Drug Act of 1983 passed, NORD represents the nearly 30 million Americans who have rare diseases with programs of advocacy, education, research, and patient services. For additional information, please visit

About PKU

PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications, including severe mental retardation and brain damage, mental illness, seizures, tremors and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. For more information about PKU, visit

About Kuvan

Kuvan(R) (sapropterin dihydrochloride) Tablets is the first and only FDA-approved prescription drug for the treatment of phenylketonuria, or PKU, a lifelong genetic metabolic disorder that, when left untreated, can result in mental retardation and other neurological problems. Individuals with PKU cannot metabolize an essential amino called phenylalanine, or Phe, which is found in most foods; this results in a dangerous accumulation of Phe in the blood, which can be toxic to the brain. Kuvan is indicated to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin - (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet. For full prescribing information, please visit

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.


    Investors:                                    Media:
    Eugenia Shen                                  Susan Berg
    BioMarin Pharmaceutical Inc.                  BioMarin Pharmaceutical Inc.
    (415) 506-6570                               (415) 506-6594

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
9. BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
10. BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. BioMarin Supports Observance of Rare Disease Day February 28
Post Your Comments:
(Date:11/24/2015)... ... 2015 , ... Young patients with a wide variety of dental needs can ... S. Lele, who are pediatric dentists in Tucson, AZ . Unlike traditional treatment ... system causes minimal discomfort and bleeding to the patient during treatment and the following ...
(Date:11/24/2015)... ... November 25, 2015 , ... ... solutions for drugs, biologics, consumer health and global clinical supply services, today announced ... upcoming Clinical Trial Supply East Asia Conference, to be held at the InterContinental ...
(Date:11/24/2015)... ... 24, 2015 , ... It takes only three to five seconds to make ... the first impression be positive and reflects business values. If a client starts with ... want to return. They will also share their thoughts about a business with others, ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... advisory organization, is pleased to welcome Winter-Dent & Company as its newest Partner ... day one to become a client's most trusted advisor regardless of whether that ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Serenity Point Rehabilitation, ... series of recent video interviews with some of the staff members at their recovery ... residential treatment facility, as well as some of the things that make their recovery ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... and BERN, Switzerland , November ... ARTORG Center for Biomedical Engineering Research of the University ... Division of Endocrinology, Diabetes and Clinical Nutrition of the ... start of an exclusive collaboration to develop a novel ... for the personalised delivery of insulin for diabetic patients ...
(Date:11/24/2015)... FLINT, Mich. , Nov. 24, 2015 Diplomat ... , Senior Vice President of Clinical Services, Education and Human ... (AIS) online webinar, "Oral Oncology Drugs: Health Plan Strategies for ... co-presenting with Beckie Fenrick , a consultant with the ... The webinar will ...
(Date:11/24/2015)... , Nov. 24, 2015 iRhythm Technologies, Inc. , ... care, today announced that it will participate in the 27th Annual ... New York, NY . Kevin King ... Tuesday December 1, 2015 at 8:50am ET. ... . --> . --> ...
Breaking Medicine Technology: